spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  MERLIN TIMI-36 

 HSMN NewsFeed - 12 Sep 2008
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 24 Apr 2008
European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 7 Dec 2007
FDA Reviewing Potential Anti-Arrhythmic Claims for Ranexa(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Nov 2007
CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Biopharmaceuticals Cardiology Endocrinology
 HSMN NewsFeed - 5 Nov 2007
Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 27 Sep 2007
CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 31 May 2007
Peter M. Strumph Named CEO of Nile Therapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 May 2007
CV Therapeutics Significantly Reduces Operating Expenses
Biopharmaceuticals
 HSMN NewsFeed - 24 Apr 2007
Journal of the American Medical Association Publishes MERLIN TIMI-36 Results
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 14 Mar 2007
JACC Publishes Long-Term Safety and Tolerability Data from Ranolazine Open Label Experience (ROLE) Program
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Mar 2007
CV Therapeutics Announces Topline MERLIN TIMI-36 Results
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Sep 2006
CV Therapeutics Completes MERLIN TIMI-36 Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 7 Jul 2006
CV Therapeutics Announces MERLIN TIMI-36 Study to Continue as Planned Based on Final Scheduled DSMB Meeting
Biopharmaceuticals Cardiology
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
MERLIN TIMI-36
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.